The biotech company is working with the National Institutes of Health , the National Institute of Allergy and Infectious Diseases , and the Vaccine Research Center on a potential vaccine, the company said in a Securities and Exchange filing.
Moderna CEO Stephane Bancel told CNBC's Becky Quick his company is working with the NIH to develop the vaccine. "They've produced a cancer vaccine in 40 days; using the same tech to do this quickly," Quick tweeted. "Moderna's mRNA vaccine technology could serve as a rapid and flexible platform that may be useful in responding to newly emerging viral threats, such as the novel coronavirus," the company said in its SEC filing. "While we have not previously tested this rapid response capability, Moderna confirms that we are working with NIH/NIAID/VRC on a potential vaccine response to the current public health emergency.